jackie.vuistiner

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator

CUTISS achieves full independence in its manufacturing capabilities with onsite facility. Increased agility and capacity in producing denovoSkin for current and future clinical trials and patients on compassionate basis. Successful transfer of technology and departure from Wyss Zurich Translational Center, a joint accelerator created by Hansjörg Wyss together with the University of Zurich and ETH …

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator Read More »

IBSA Pharma and CUTISS complete license agreement for VitiCell

PRESS RELEASE  Two innovative biotechnology specialists, IBSA Pharma and CUTISS complete license agreement for VitiCell® Agreement grants CUTISS exclusive worldwide license to commercialize VitiCell®. VitiCell® is a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Strategic fit with CUTISS’s expertise in skin tissue bioengineering. Sophia-Antipolis (France) and Zurich (Switzerland), 2 …

IBSA Pharma and CUTISS complete license agreement for VitiCell Read More »

CUTISS opens R&D subsidiary in France and secures first grant

CUTISS opens subsidiary in France and secures first government grant to extend its Research and Development in regenerative medicine The subsidiary CUTISS Innovation, based at Sophia Antipolis, Europe’s leading technology park, will focus on R&D and innovation in regenerative medicine. A grant of EUR 300,000 from the Region Provence-Alpes-Cote d’Azur will contribute towards the installation …

CUTISS opens R&D subsidiary in France and secures first grant Read More »

Swissmedic grants CUTISS certificates of Good Manufacturing and Distribution Practices

CUTISS’s first onsite manufacturing facility in Schlieren, Zurich, has received the certification of compliance for Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) from the regulator Swissmedic, the Swiss Agency for Therapeutic Products. The GMP and GDP certifications authorizes the collection, manufacturing, testing, storage, release, and distribution of Transplant Products (TpP), Gene Therapy (GT) …

Swissmedic grants CUTISS certificates of Good Manufacturing and Distribution Practices Read More »

Journal of Wound Care: The future of bioengineering personalized skin

As part of the journal’s “Innovations in wound care” section, the latest edition features a guest editorial by our CEO Daniela Marino and CIO Vincent Ronfard. When patients suffer from large and severe skin injuries affecting more than 50% of the body, such as burns, then the current standard of care – autografting – presents …

Journal of Wound Care: The future of bioengineering personalized skin Read More »

CUTISS’s skin tissue graft is granted US patent

We are pleased to announce that a tissue graft patent has been granted by the United States Patent and Trademark Office (USPTO) for the personalized bioengineered human skin tissue therapy developed by CUTISS. The patent (U.S. Patent no. 10,953,140 B2) has been granted to University of Zurich (UZH) where the founders of CUTISS worked at …

CUTISS’s skin tissue graft is granted US patent Read More »

Article TOP 100 Swiss Startup Award 2021

Article published by Isabelle Mitchell, Top 100 Swiss Startup Magazine 2021 on 08.09.2021 20:32 Last year’s winner is this year’s runner-up: The CUTISS team wins silver at the TOP 100 Swiss Startup Award 2021 for developing unique personalized skin technology to treat skin defects. CUTISS’s denovoSkin™ is a safe, effective, and accessible therapy for children …

Article TOP 100 Swiss Startup Award 2021 Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.